Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company^TM, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted a non-qualified stock option award to purchase an aggregate of 200,000 shares of its Class A common stock to one new employee under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan (the “2023 Inducement Plan”). The stock options were granted as inducements material to the new employee becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si (or following a bona fide period of non-employment), as an inducement material to such individuals’ entering into employment with Quantum-Si, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $2.09 per share, which is equal to the closing price of Quantum-Si’s Class A common stock on The Nasdaq Global Market on August 15, 2023, the date of grant of the options. Each option will vest over a four-year period, with 25% of the shares vesting on the last day of the calendar quarter that is 12 months after the employee’s start date and the remaining shares vesting monthly over the following 36-months, subject to the employee’s continued employment with Quantum-Si on such vesting dates. The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company^TM, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.

Contacts

Investors
Juan Avendano
ir@quantum-si.com

Media
Michael Sullivan
media@quantum-si.com

First published on Thu, Aug 17, 2023

Enjoyed what you read? Great news – there’s a lot more to explore!

Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!

Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.

Head to the TechDogs homepage to Know Your World of technology today!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

Quantum-Si Protein Sequencing Company Digitize Proteomic Research

Join The Discussion

BioTechnology

Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Join Our Newsletter